Pharmaceutical supply chains are facing a new era of unprecedented strain as geopolitical disruption, manufacturing weaknesses, cyber threats, and counterfeit medicines converge, according to a new report from Moody’s.
The report emphasizes these are no longer isolated events but increasingly interconnected crises. Companies managing supply chain, cyber, and operational risks in silos are reducing their ability to anticipate disruption.
Geopolitical instability is directly impacting global medicine flows. The Red Sea crisis has cut Suez Canal traffic, forcing costly reroutes. Instability in the Middle East pressures active pharmaceutical ingredients from key hubs, while potential US tariffs on imported medicines could cost tens of billions.
Manufacturing remains a fragile link. Sterile injectable facilities are at high utilization, and regulatory hurdles prevent rapid alternative production. The 2023 collapse of Akorn Pharmaceuticals demonstrated how concentrated supply chains can immediately vanish without replacement.
Cybersecurity creates another acute vulnerability. The Change Healthcare ransomware attack disrupted thousands of pharmacies, while reliance on AI and cloud systems introduces new data integrity risks. Simultaneously, counterfeit medicines are harder to detect in expanding online markets.
Moody’s warns that companies must adopt a connected resilience approach, improving visibility across the entire network as shortages become driven by multiple overlapping risks.